Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females

Figure 9

Antibody titers in women 15–55 years of age seronegative at baseline in the ATP cohort over time [71]. GMT means geometric mean titre and is shown with 95% confidence intervals; EU/mL = ELISA units per milliliter. Arrows indicate the vaccination time points (months 0, 1, and 6). Seropositivity is defined as ≥8 EU/mL for anti- HPV-16 and ≥7 EU/mL for anti-HPV-18. Natural infection is from the GMTs in women seropositive DNA-negative for HPV-16 and HPV-18 from the PATRICIA trial [129].

(a) Fold higher than natural infection titers at 48 months after first vaccination: 18-fold higher than NIT for women 26–45 years old, and 11-fold higher for women 46–55 years old [131]

(b) Fold higher than natural infection titers at 48 months after first vaccination: 8-fold higher than NIT for women 26–45 years old, and 5-fold higher for women 46–55 years old [131]